During the long downturn in R&D productivity, a handful of biopharmaceutical companies have consistently bucked the trend. How did they manage it? After all, they have experienced the same industry pressures as their peers - pressures such as lengthier R&D cycle times, higher costs of failure, and sharper regulatory scrutiny.
As pharmaceutical companies have expanded target markets and outsourced production over the last decade, the supply chain has become increasingly global, virtual and vulnerable. As a result, counterfeit activity is thriving - and patients have suffered and died from counterfeit and contaminated drugs.
RFID technology company eAgile is marketing a solution known as eSeal that aims to enable the automatic tracking of containers of medication from the point of manufacture to the drugstore counter or a patient's hospital bedside.
Hope and expectation surround the chemical industry's increasing adoption of biotechnological manufacturing - but today, their lengthy development times and complex processes mean frustration is a major byproduct.